SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
Malignant melanoma is the most aggressive skin cancer and can only be cured if detected early. Unfortunately, later stages of the disease do not guarantee success due to the rapid rate of melanoma cell metastasis and their high resistance to applied therapies. The search for new molecular targets an...
Main Authors: | Iwona Karwaciak, Anna Sałkowska, Kaja Karaś, Marta Sobalska-Kwapis, Aurelia Walczak-Drzewiecka, Łukasz Pułaski, Dominik Strapagiel, Jarosław Dastych, Marcin Ratajewski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/5/673 |
Similar Items
-
Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism
by: Iwona Karwaciak, et al.
Published: (2021-05-01) -
Identification of Novel Molecular Markers of Human Th17 Cells
by: Anna Sałkowska, et al.
Published: (2020-07-01) -
5-((3-Amidobenzyl)oxy)nicotinamides as SIRT2 Inhibitors: A Study of Constrained Analogs
by: Teng Ai, et al.
Published: (2023-11-01) -
Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce <i>IL6</i> in Monocytes and Macrophages—Potential Implications for Cytokine Storm Syndrome
by: Iwona Karwaciak, et al.
Published: (2021-01-01) -
SARS-CoV-2 Proteins Induce <i>IFNG</i> in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors
by: Anna Sałkowska, et al.
Published: (2020-11-01)